Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by cholestasis and, in later stages, cirrhosis. PBC has no cure; current treatment options only halt or slow the progression of liver disease and reduce the need for liver transplantation. Ursodeoxycholic acid (UDCA) is the cornerstone of treatment; Intercept’s Ocaliva (obeticholic acid) has been an option for patients who respond inadequately or cannot tolerate UDCA, despite the risk of serious liver injury. PPAR agonists (Ipsen’s Iqirvo [elafibranor]) and (Gilead’s Livdelzi [seladelpar]) are a new class of drugs available for PBC. Although the drugs improve outcomes, they do not address the underlying autoimmune defect or meaningfully improve symptoms. This analysis of U.S. patient-level claims data, collected through Q2 2024, explores the use of key PBC therapies, including numerous symptomatic treatments, in both newly diagnosed and recently treated patients, providing insight into the treatment paradigm for PBC.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PBC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PBC patients?
• How have UDCA and Ocaliva been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of PBC patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of PBC patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Content highlights

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Ursodeoxycholic acid, obeticholic acid, fibrates, oral corticosteroids, SSRIs, statins, oral immunosuppressants

Key analyses

• Brand / therapy usage across longitudinal patient sample
• Newly diagnosed patient analysis
• Treatment initiation and progression
• Line of therapy analysis
• Combination therapy analysis
• Source of business for recently treated patients
• Persistency and compliance analysis
• Product-level patient flow charts

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses